Rationally designed antibodies
AssigneeAlexion Pharmaceuticals, Inc.
InventorsKatherine S. Bowdish, Shana Frederickson, Mark Renshaw
Life of this patent
Estimating the term…
Abstract
Antibodies or fragments thereof having at least two CDR regions replaced or fused with biologically active peptides are described. Compositions containing such antibodies or fragments thereof are useful in therapeutic and diagnostic modalities.
Claims65
An immunoglobulin molecule or fragment thereof comprising atleast a first thrombopoietin (TPO) peptide mimetic and atleast a second TPO peptide mimetic, wherein the first TPO peptide mimetic replaces a single portion of a first complementarity determining region (CDR), said portion comprising one or more contiguous amino acid residues of the first CDR, and the second TPO peptide mimetic replaces a single portion of a second CDR, said portion comprising one or more contiguous amino acid residues of the second CDR, and wherein the immunoglobulin molecule or a fragment thereof binds to and agonizes a TPO receptor.
An immunoglobulin molecule or fragment thereof comprising a complementarity determining region (CDR) wherein a peptide mimetic comprising SEQ ID NO. 126 replaces a single portion of said CDR, said portion comprising one or more contiguous amino acid residues, wherein Xaa at each occurrence represents any amino acid, and wherein the immunoglobulin molecule or a fragment thereof binds to and agonizes a TPO receptor.
An immunoglobulin molecule or fragment thereof comprising at least a first agonist peptide mimetic and at least a second agonist peptide mimetic, wherein the first agonist peptide mimetic replaces a single portion of a first complementarity determining region (CDR), said portion comprising one or more contiguous amino acid residues of the first CDR, and the second agonist peptide mimetic replaces a single portion of a second CDR, said portion comprising one or more continuous amino acid residues of the second CDR, and wherein the immunoglobulin molecule or a fragment thereof binds to and agonizes a receptor.
An immunoglobulin molecule or fragment thereof comprising at least a first erythropoietin (EPO) peptide mimetic and at least a second EPO peptide mimetic, wherein the first EPO peptide mimetic replaces a single portion of a first complementarity determining region (CDR), said portion comprising one or more contiguous amino acid residues of the first CDR, and the second EPO peptide mimetic replaces a single portion of a second CDR, said portion comprising one or more contiguous amino acid residues of the second CDR, and wherein the immunoglobulin molecule or a fragment thereof binds to and agonizes an EPO receptor.
Dependencies are inferred from the claim text.